Fatal hyalohyphomycosis with cutaneous involvement caused by Purpureocillium lilacinum in an immunocompromised patient with bullous pemphigoid.

Marialuisa Corbeddu; Caterina Ferreli; Riccardo Cappai; Patrizia Ferraguti; Laura Atzori; Luca Pilloni; Franco Rongioletti

doi:10.23750/abm.v92i3.10100

Fatal hyalohyphomycosis with cutaneous involvement caused by Purpureocillium lilacinum in an immunocompromised patient with bullous pemphigoid.

Authors

Marialuisa Corbeddu Unit of Dermatology, Department of Medical Science and Public Health, University of Cagliari
Caterina Ferreli Unit of Dermatology, Department of Medical Science and Public Health, University of Cagliari
Riccardo Cappai Laboratory Clinical Chemical Analysis and Microbiology University Hospital of Cagliari
Patrizia Ferraguti Laboratory Clinical Chemical Analysis and Microbiology University Hospital of Cagliari
Laura Atzori Unit of Dermatology, Department of Medical Science and Public Health, University of Cagliari
Luca Pilloni Unit of Pathology, Department of Medical Science and Public Health, University of Cagliari
Franco Rongioletti Unit of Dermatology, Department of Medical Science and Public Health, University of Cagliari

DOI: https://doi.org/10.23750/abm.v92i3.10100

Keywords:

Hyalohyphomycosis, Purpureocillium lilacinum, Bullous pemphigoid, Bio-pesticides, Cellulitis

Abstract

Emergent pathogen as Purpureocillium lilacinum are becoming cause of morbidity and mortality in our population, especially in immunocompromised patients. We describe a case of hyalohyphomycosis in a diabetic man under systemic steroid treatment for a bullous pemphigoid. Treatment with different antimycotic drugs were ineffective and infection spread diffusely, leading to deterioration of general conditions and ultimately death. The aim of this article is to increase awareness of clinicians about this uncommon, but frequently fatal refractory mycotic infection.

References

1. Pastor FJ, Guarro J. Clinical manifestations, treatment and outcome of Paecilomyces lilacinus infections. Clinical Microbiology and Infection. 2006.
2. Carey J, D’Amico R, Sutton DA, Rinaldi MG. Paecilomyces lilacinus vaginitis in an immunocompetent patient. Emerg Infect Dis. 2003 Sep 1;9(9):1155–8.
3. Rousidou C, Papadopoulou ES, Kortsinidou M, Giannakou IO, Singh BK, Menkissoglu-Spiroudi U, et al. Bio-pesticides: Harmful or harmless to ammonia oxidizing microorganisms? The case of a Paecilomyces lilacinus-based nematicide. Soil Biol Biochem. 2013 Dec;67:98–105.
4. Antas PRZ, Brito MMS, Peixoto É, Ponte CGG, Borba CM. Neglected and emerging fungal infections: Review of hyalohyphomycosis by Paecilomyces lilacinus focusing in disease burden, in vitro antifungal susceptibility and management. Microbes and Infection. 2012.
5. L. Ajello and M.R. McGinnis, ‘Nomenclature of Human Pathogenic Fungi. In Grundlagen Der Antiseptik: Part 4. Factoren Der Mikrobiellen Kolonisation’ (A. P. Krasilnikow et al. Berlin: Verlag Volk und Gesundheit, 1984), 363–77.
6. Gutiérrez-Rodero F, Moragón M, Ortiz De La Tabla V, Mayol MJ, Martín C. Cutaneous hyalohyphomycosis caused by Paecilomyces lilacinus in an immunocompetent host successfully treated with itraconazole: Case report and review. Eur J Clin Microbiol Infect Dis. 1999.
7. Castelli MV, Alastruey-Izquierdo A, Cuesta I, Monzon A, Mellado E, Rodriguez-Tudela JL, et al. Susceptibility testing and molecular classification of Paecilomyces spp. Antimicrob Agents Chemother. 2008 Aug;52(8):2926–8.
8. Rimawi RH, Carter Y, Ware T, Christie J, Siraj D. Use of Voriconazole for the Treatment of Paecilomyces lilacinus Cutaneous Infections: Case Presentation and Review of Published Literature. Mycopathologia. 2013.
9. Almeida Oliveira M, Carmo A, Rosa A, Murta J. Posaconazole in the treatment of refractory purpureocillium lilacinum (former paecilomyces lilacinus) keratitis: The salvation when nothing works. BMJ Case Rep. 2019 Apr 1;12(4).
10. Chen W, Lin S, Hung S. Successful Treatment of Recurrent Cutaneous Purpureocillium lilacinum (Paecilomyces lilacinus) Infection with Posaconazole and Surgical Debridement. Acta Derm Venereol. 2019;0.
11. McCarthy M, Rosengart A, Schuetz AN, Kontoyiannis DP, Walsh TJ. Mold infections of the central nervous system. Vol. 371, New England Journal of Medicine. Massachussetts Medical Society; 2014. p. 150–60.
12. Verma R, Singh P, Kumar A, Paliwal VK. Cranial aspergilloma masquerading as meningioma. BMJ Case Rep. 2013;
13. Henry ME, Bolo NR, Zuo CS, Villafuerte RA, Cayetano K, Glue P, et al. Quantification of brain voriconazole levels in healthy adults using fluorine magnetic resonance spectroscopy. Antimicrob Agents Chemother. 2013 Nov;57(11):5271–6.